Appili Therapeutics Inc (APLI) Fair Value & Analysis
Healthcare · CA · Market cap C$2.0M (≈ $1.4M) · ISIN CA03783R1073
What is Appili Therapeutics Inc really worth?
Below-average quality, trading 30% below our fair value of C$0.0143.
As of Jun 26, 2026, the fair value of Appili Therapeutics Inc is C$0.0143 per share against a price of C$0.0100, so the fair value sits 43% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Jun 26, 2026
From 6 valuation models · updated 71 days ago
Fair value updated Jun 26, 2026, revised from C$0.0100 to C$0.0143 (+43.0%) since Jun 24, 2026. Share price −33.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (31/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (C$0.0143). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 26, 2026.
How to read this chart
60‑month range C$0.0100 – C$1.08 · the C$0.0100 price screens below the C$0.0143 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 26, 2026.
Analysis
Appili Therapeutics Inc (APLI) currently trades at C$0.0100, while our model-based Fair Value estimate is C$0.0143, implying the stock looks roughly 30.1% undervalued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 6 models at a data quality of 95/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at C$206K. Revenue grew 6.1% year over year. Net debt stands at C$12.9M. Fundamentals as of Jun 26, 2026
The share trades about 75% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at 43%, APLI screens cheaper than that median.
Notify me when APLI reaches fair value
Put APLI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 26, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada.
Full company description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Appili Therapeutics Inc reported revenue of C$244K in FY2026 versus C$1.4M in FY2022, a compound −35.3%/yr. Reported net income was −C$4.2M in FY2026.
Watch APLI: get an alert when its fair value changes →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Appili Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Appili Therapeutics Inc (APLI) overvalued or undervalued?
What is the fair value of APLI?
What is the quality score of APLI?
What is the price target for Appili Therapeutics Inc (APLI)?
What is the Appili Therapeutics Inc stock forecast for 2026?
What is the revenue of Appili Therapeutics Inc (APLI)?
What is the net profit margin of APLI?
Watch Appili Therapeutics Inc in the live analysis
One click puts Appili Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.